Brainwaves Meet Spatial Computing: Cognixion + Vision Pro

The partnership between Cognixion and Apple Vision Pro represents something bigger than a clever product integration. It represents the maturation of non-invasive brain-computer interface technology reaching beyond laboratory settings into a mainstream platform with millions of potential users. In October 2025, Cognixion launched its clinical trial pairing a custom EEG headband with the Vision Pro, and the implications ripple far beyond the patients with ALS or spinal cord injuries who are the immediate beneficiaries. This convergence of technologies signals a fundamental shift in how we think about accessibility, human agency, and what it means to restore communication to people who have lost their voice.

For anyone following the brain-computer interface space, the news might seem surprising at first glance. Elon Musk's Neuralink has dominated headlines with its ambitious vision of brain implants for everyone, and Synchron has generated excitement with its minimally invasive stent-like electrodes threaded into blood vessels near the brain. Both approaches have merit. But Cognixion took a different path entirely. Instead of cutting into the brain or threading electrodes into vessels, the company built a solution that works from the outside of the head, reading electrical signals through the scalp using the same EEG sensors you might find in a neuroscience lab. That simplicity masks profound technical achievement and explains why the company was named to TIME's Best Inventions of 2025 earlier this month.

The Technical Architecture: EEG Meets Augmented Reality

To understand why this integration matters, you need to know how Cognixion actually works. The company's flagship system, called Axon-R, uses six to eight strategically placed EEG sensors positioned over the occipital and parietal regions of the scalp. These regions are responsible for processing visual information and spatial attention, which is why they're perfect for detecting a specific neural signature called steady-state visually evoked potential, or SSVEP. When a person focuses their mental attention on a flickering visual stimulus on a screen, the brain generates a measurable electrical response at that exact frequency. By monitoring for these responses in real time, the system can decode where a person is looking and what they intend to select, all without them moving a muscle.

This is where the Vision Pro integration becomes elegant. Instead of replacing the Vision Pro's entire interface, Cognixion simply swaps out Apple's standard headband for one embedded with its EEG sensors. The spatial computing display becomes the visual stimulus. An external neural processing unit, worn at the hip, handles the heavy computation of translating raw brain signals into actionable commands. The combined system then leverages Apple's already world-class accessibility architecture, including Eye Tracking for gaze input and Dwell Control, which lets users select items by holding their gaze. It's a beautiful example of specialization and integration working together.

What separates this from earlier attempts at brain-computer interfaces is the addition of artificial intelligence. Cognixion's system doesn't just detect visual attention. It feeds those signals into a large language model that has been trained specifically on each individual user's communication patterns. The AI learns how a person speaks, their humor style, their writing history, their preferred expressions. During the clinical trials, participants were asked to provide emails, texts, voice recordings, and other written samples so the system could understand their unique voice. When the user focuses on visual options in the AR interface, the AI generates not just rigid menu items but contextually appropriate suggestions that sound like them. One participant in earlier trials, a rabbi with ALS who had been communicating through eye movements alone for years, was able to engage in fluent, nuanced conversation approaching the speed of natural speech. That's not technology speaking for him. That's technology helping him speak like himself.

The Vision Pro Advantage: Beyond Isolated Communication

This is where most people miss the real significance of the partnership. Earlier Cognixion systems, while groundbreaking, were purpose-built communication devices. You put on the headset, you select from a menu, you compose a message or response. It works beautifully for what it was designed to do, but your options are constrained by the interface developers' imagination. The Vision Pro changes that fundamentally. Apple's spatial computing platform gives you access to the entire app ecosystem. Email, messaging, web browsing, productivity software, entertainment, social media. A paralyzed person using Cognixion with a standalone device might communicate. A paralyzed person using Cognixion with the Vision Pro can actually live in digital space the way anyone else does.

This matters profoundly for dignity and independence. There's a psychological difference between a communication aid and a computer you control. One is remedial. The other is empowering. The Vision Pro, for all its critiques and challenges in the broader consumer market, has an accessibility-first design philosophy baked into its DNA. Eye tracking is built in. Head tracking is built in. The underlying accessibility architecture includes switch control, voice control, and compatibility with external accessibility hardware. Cognixion's EEG module becomes another input method in an ecosystem already designed to accommodate multiple ways of interacting. That's not accidental. It's intentional design by Apple and deliberate partnership building by Cognixion.

The clinical trial, which launched in October 2025 and will run through April 2026, is testing exactly this vision with up to 10 participants living with ALS, spinal cord injuries, stroke, or traumatic brain injury. The researchers are measuring information transfer rate (how much information can be communicated per minute), system usability, and crucially, how much personalization through AI actually improves the user experience. These aren't abstract metrics. Information transfer rate directly correlates to how naturally someone can hold a conversation. System usability determines whether a device becomes a tool people actually use or something that sits in a drawer. And personalization through AI is what makes the experience feel less like operating a machine and more like expressing yourself.

The Impressive Accomplishments

Let's be direct about what Cognixion has already achieved. The company raised $25 million in funding from organizations like Prime Movers Lab and the Amazon Alexa Fund, demonstrating serious institutional confidence. It received FDA Breakthrough Device designation in May 2023, an honor that puts the company on an expedited review pathway and signals to the regulatory world that this technology could materially improve lives. Being named to TIME's Best Inventions of 2025 is historically significant because TIME had previously recognized invasive neurotechnology devices like deep-brain stimulation systems, but Cognixion's recognition marks the first time a completely non-invasive, wearable brain-computer interface has received such distinction.

The clinical evidence is compelling. In earlier trials with the standalone Axon-R system, participants achieved communication speeds approaching normal conversation. One rabbi with late-stage ALS was able to respond to questions, tell jokes, and engage in substantive dialogue at speeds that made real conversation possible. He'd been locked in for nearly a decade, communicating through eye movements alone, laboriously spelling out one letter at a time. Suddenly he could express complete thoughts. The psychological impact cannot be overstated. People in locked-in syndrome have devastatingly high rates of depression and hopelessness. The difference between communicating a single letter every few minutes and engaging in natural conversation is the difference between isolation and connection.

The company has also demonstrated remarkable pragmatism in regulatory strategy. Rather than trying to jump straight to a large pivotal trial, Cognixion has structured a logical progression. The Vision Pro clinical trial with up to 10 patients is generating real-world evidence of usability and efficacy. Data from this will inform a larger pivotal trial involving approximately 30 patients, which is typically what the FDA requires for medical device clearance. This staged approach is smart. It generates evidence efficiently, it builds confidence with regulators, and it de-risks the path to commercialization. CEO Andreas Forsland has publicly stated the company expects faster patient access through non-invasive approaches compared to invasive competitors still working through initial human trials.

The Genuine Limitations Worth Understanding

But honesty requires acknowledging the technical challenges that still exist. EEG-based systems fundamentally face a signal-to-noise problem that invasive approaches don't. Your skull, while necessary for protecting your brain, is not transparent to electrical signals. The higher frequency signals that could provide richer information about brain activity get attenuated by the time they reach surface electrodes. This is why invasive methods like Neuralink's Utah microarray electrodes, which sit directly on brain tissue, can achieve signal quality and information transfer rates that non-invasive systems still struggle to match. A comprehensive review of EEG-based imagined speech decoding published in 2022 found that invasive methods like electrocorticography regularly exceed 70% accuracy in classification tasks, while non-invasive EEG methods often fall short of that threshold. Cognixion's system gets around this partly through clever signal processing and partly through the SSVEP approach, which is specifically designed to work with scalp EEG, but it's still fighting physics.

There's also the challenge of user variability. Not everyone's brain generates equally strong visual evoked potentials. Some people are what researchers call BCI illiterate, meaning their brain doesn't produce the signatures the system is looking for, or the signatures are too weak to reliably decode. Cognixion has worked to address this through AI adaptation and multimodal input (combining brain signals with eye tracking and head movement), but this remains an open problem in the field. The company isn't hiding this. The clinical trial is specifically designed to identify individual factors that affect communication speed and to optimize the system for each person's unique neural signature.

The Vision Pro itself has limitations as a platform. Apple's spatial computing headset launched to mixed consumer adoption and faced criticism for its weight, battery life, heat generation, and limited initial app ecosystem. For users with severe motor impairments, the Vision Pro's 645-gram weight might be manageable while wearing a headstand or support structure, but for extended periods, comfort becomes a real consideration. The technology is also expensive. A Vision Pro costs $3,500. Adding Cognixion's custom EEG module and processing hardware will add thousands more. This isn't a consumer device for typical patients. It's a medical device with premium pricing.

There's also a legitimate question about whether this specific combination is the permanent solution or an interim stepping stone. Apple might develop its own integrated neural sensing capabilities in future Vision Pro versions. Other companies might build smaller, lighter, more power-efficient spatial computing platforms optimized for assistive applications. The Cognixion-Vision Pro partnership is groundbreaking, but it's also a moment in time, representing what's possible with current technology, not necessarily what the final solution will look like five years from now.

Why This Matters More Than the Headlines Suggest

The broader significance of this partnership lies in what it represents about the trajectory of neurotechnology. The BCI market is projected to grow from approximately $2.4 billion in 2025 to somewhere between $12 billion and $19 billion by 2035, depending on which market research firm you consult. The critical insight from all the forecasts is consistent: the non-invasive segment is expected to capture more than 55% of the total market. This isn't because invasive systems won't work well. It's because accessibility, safety, and speed to deployment matter more than ultimate signal quality for most applications and most patients.

Cognixion's approach exemplifies this economic and practical reality. A patient with ALS doesn't have years to wait for Neuralink to complete clinical trials and receive FDA clearance and establish surgical centers nationwide. They have months or years before locked-in syndrome progresses to the point where even eye tracking becomes difficult. A non-invasive solution that works reasonably well and can be deployed immediately has enormous value, even if an invasive solution might ultimately be slightly superior. Add to that the elimination of surgical risk, the ability to try the technology before committing, the potential for rapid iteration as software improves, and the safety profile that doesn't require patients to worry about infection, scarring, or immune rejection, and you understand why the industry is moving toward non-invasive solutions as the dominant paradigm.

The Apple partnership also signals something important about mainstream technology companies recognizing the ethical imperative of accessibility. Apple has built its marketing brand partly on accessibility, more so than any other major tech company. Tim Cook has spoken publicly about seeing assistive technology as a fundamental human right. The partnership with Cognixion puts Apple's money where its mouth is. It's not adding a checkbox to an accessibility feature matrix. It's integrating a brain-computer interface into a major platform, investing in clinical research, and creating a pathway for millions of people with motor impairments to access not just communication but full digital agency.

This also matters for how we think about the future of human-computer interaction more broadly. Apple's accessibility features like Eye Tracking, Dwell Control, and Switch Control were designed to make existing interfaces accessible to people with disabilities. Cognixion inverts that framework. Instead of adapting an interface for disabled users, Cognixion makes disabled users' neural signals an input method equal in power to anyone else's hands or voice. That's a philosophical shift, not just a technical one. It's saying that your brain state is as valid an interface as your fingers or your eyes. It's saying that thought-driven interaction isn't a workaround for people with disabilities. It's a fundamental input method for computing.

The Realistic Path Forward

If you're thinking about the future of this technology, the realistic trajectory matters. The clinical trial running through April 2026 will generate crucial data. If the system demonstrates genuine usability improvements and acceptable communication speeds with the Vision Pro compared to Cognixion's standalone system, it strengthens the case for FDA approval and commercialization. Positive results also open doors for insurance coverage and hospital adoption, which is the difference between a technology remaining in research settings versus reaching patients who need it.

The pivotal trial with 30 patients will likely follow in 2026 or 2027. FDA approval, if the data supports it, could come in 2027 or 2028. Even with Breakthrough Device designation expediting the process, medical device regulatory pathways are intrinsically lengthy. But Cognixion has a clear stated goal of reaching more than 3 million users by 2035. That's ambitious but not impossible if the technology works as intended and pricing becomes more accessible through volume manufacturing and insurance coverage.

What seems almost certain is that this isn't the final form of the technology. The Vision Pro might be involved in future iterations, or Cognixion might develop its own spatial computing platform. Other companies will absolutely develop competing non-invasive BCI systems integrated with various platforms. The market is too large and the need is too acute for Cognixion to remain a monopoly player. But what's less certain is whether non-invasive approaches will improve fast enough to match the signal quality that invasive systems can achieve. That's the technical race that will define the field over the next decade.

Conclusion: A Door Opening, Not Slamming Shut

The partnership between Cognixion and Apple Vision Pro isn't the culmination of brain-computer interface technology. It's a significant milestone in a longer journey toward making neural interfaces practical, accessible, and integrated into mainstream platforms. The technology works. Early clinical evidence demonstrates that non-paralyzed volunteers and patients with neurodegenerative conditions can control the system and communicate at speeds and with natural nuance previously impossible with older AAC devices. The regulatory pathway is clear, even if it's not fast.

What makes this partnership particularly noteworthy is how it sidesteps the either-or thinking that has dominated BCI discourse. You don't need to choose between safety and capability, between invasive and non-invasive, between specialized assistive devices and mainstream platforms. Cognixion chose a path that optimizes for speed, safety, and accessibility. Apple chose to open its platform to neurotechnology integration. The result is something that didn't exist a year ago: a commercially available spatial computing platform that can be controlled through brain signals, tested in clinical trials with genuine patients, and iterated on continuously as software improves.

That's worth paying attention to, even if headlines are already moving on to the next Neuralink update or the next consumer neurotech gadget. The quieter stories about pragmatic, non-invasive solutions reaching real patients often matter more than the noisier stories about ambitious moonshot technologies. Cognixion is writing that quieter story. And judging by TIME's recognition, the broader world is starting to notice what neuroscientists and biomedical engineers already knew. The brain-computer interface isn't coming. For people with ALS, spinal cord injuries, and locked-in syndrome, it's already here.

References

Amazon Alexa Fund. (2025). Investment in Cognixion for noninvasive brain-computer interface development. Retrieved from https://www.cognixion.com

Apple Inc. (2025). visionOS 26: New spatial computing features.  https://www.apple.com/newsroom/2025/06/visionos-26-introduces-powerful-new-spatial-experiences-for-apple-vision-pro/

Cognixion. (2024). Cognixion Axon-R recognized as TIME Best Inventions of 2025. https://www.cognixion.com/blog/2025/10/21/time-best-inventions-of-2025-x-cognixion

Cognixion. (2025). Clinical trial news: Cognixion launches augmented reality BCI longitudinal study. https://clinicaltrials.gov/study/NCT07209943

Cognixion. (2025). Redefining accessibility: How Apple Vision Pro and Cognixion are advancing non-invasive brain-computer interfaces. https://www.cognixion.com/blog/2025/10/29/apple-work-cognixion-episode-l8t26

Cognixion. (2025). Unlocking communication: Cognixion launches clinical study integrating noninvasive BCI with Apple Vision Pro. https://www.cognixion.com/blog/2025/10/21/cognixion-x-apple-vision-pro

Cognixion. (2023). Cognixion receives FDA Breakthrough Device designation. https://www.cognixion.com/blog/2023/5/3/cognixion-receives-fda-breakthrough-device-designation-for-its-brain-computer-interface

Forbes. (2025). This startup lets paralyzed people use computers without a chip in their head. https://www.forbes.com/sites/alexknapp/2025/03/12/this-startup-lets-paralyzed-people-use-computerswithout-a-chip-in-their-head/

Forbes. (2025). These are the startups merging your brain with AI. https://www.forbes.com/sites/robtoews/2025/10/05/these-are-the-startups-merging-your-brain-with-ai/

MacRumors. (2024). Apple Vision Pro can now be controlled with brain-computer interface. https://www.macrumors.com/2024/07/30/vision-pro-can-now-be-controlled-with-brain/

Prophecy Market Insights. (2024). Brain computer interface market size, share & growth report 2035. https://www.prophecymarketinsights.com/market_insight/brain-computer-interface-market-5801

Roots Analysis. (2025). Brain computer interface market till 2035. https://www.rootsanalysis.com/brain-computer-interface-market

Sereshkeh, A.R., et al. (2018). EEG classification of covert speech for brain computer interfaces using hidden Markov models. Journal of Neural Engineering, 14(4), 046006.

Technology Networks. (2025). The promise and challenges of brain-computer interfaces.  https://www.technologynetworks.com/informatics/articles/the-promise-and-challenges-of-braincomputer-interfaces-397268

TIME. (2025). Best inventions of 2025: Cognixion Axon-R. Time Magazine.

Wired. (2025). This startup wants to put its brain-computer interface in the Apple Vision Pro. https://www.wired.com/story/this-startup-wants-to-put-its-brain-computer-interface-in-the-apple-vision-pro/

Wall Street Journal. (2026). Tech that will change your life in 2026. https://www.linkedin.com/posts/rmazzini_so-happy-to-see-cognixion-included-in-the-activity-7415050934508081152-pZYD